Literature DB >> 26838061

Nonessential amino acid metabolism in breast cancer.

Renee C Geck1, Alex Toker2.   

Abstract

Interest in studying cancer metabolism has risen in recent years, as it has become evident that the relationship between cancer and metabolic pathways could reveal novel biomarkers and therapeutic targets. Metabolic starvation therapy is particularly promising due to its low toxicity. Nonessential amino acids are promising metabolites for such therapy because they become essential in many tumor cells, including breast cancer cells. This review will focus on four nonessential amino acid metabolism pathways: glutamine-glutamate, serine-glycine, cysteine, and arginine-proline metabolism. Recent studies of these amino acids have revealed metabolic enzymes that have the potential to be effective as cancer therapy targets or biomarkers for response to metabolic starvation therapy. The review will also discuss features of nonessential amino acid metabolism that merit further investigation to determine their relevancy to breast cancer treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amino acid; Breast cancer; Cancer therapy; Tumor metabolism

Mesh:

Substances:

Year:  2016        PMID: 26838061     DOI: 10.1016/j.jbior.2016.01.001

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  25 in total

1.  Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer.

Authors:  Chen Dai; Verodia Charlestin; Man Wang; Zachary T Walker; Maria Cristina Miranda-Vergara; Beth A Facchine; Junmin Wu; William J Kaliney; Norman J Dovichi; Jun Li; Laurie E Littlepage
Journal:  Cancer Res       Date:  2020-07-06       Impact factor: 12.701

Review 2.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

3.  Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics.

Authors:  Zhitao Ni; Shaolin Xu; Zheng Yu; Zhongjiang Ye; Rongqi Li; Chuang Chen; Jianhui Yang; Huamin Liu; Ziye Zhou; Xiuhua Zhang
Journal:  Invest New Drugs       Date:  2022-09-05       Impact factor: 3.651

4.  Genetic analysis of Pycr1 and Pycr2 in mice.

Authors:  Morgane G Stum; Abigail L D Tadenev; Kevin L Seburn; Kathy E Miers; Pak P Poon; Christopher R McMaster; Carolyn Robinson; Coleen Kane; Kathleen A Silva; Paul F Cliften; John P Sundberg; Laura G Reinholdt; Simon W M John; Robert W Burgess
Journal:  Genetics       Date:  2021-05-17       Impact factor: 4.562

Review 5.  Targeting GLS1 to cancer therapy through glutamine metabolism.

Authors:  Wei Yu; XiangYu Yang; Qian Zhang; Li Sun; ShengTao Yuan; YongJie Xin
Journal:  Clin Transl Oncol       Date:  2021-05-23       Impact factor: 3.405

6.  Glutamate blunts cell-killing effects of neutrophils in tumor microenvironment.

Authors:  Tiantian Xiong; Ping He; Mi Zhou; Dan Zhong; Teng Yang; Wenhui He; Zhizhen Xu; Zongtao Chen; Yang-Wuyue Liu; Shuang-Shuang Dai
Journal:  Cancer Sci       Date:  2022-04-24       Impact factor: 6.518

Review 7.  Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.

Authors:  Lin Zhao; Yuanyuan Liu; Simiao Zhang; Lingyu Wei; Hongbing Cheng; Jinsheng Wang; Jia Wang
Journal:  Cell Death Dis       Date:  2022-04-20       Impact factor: 9.685

8.  Tissue metabolic profiling of human gastric cancer assessed by (1)H NMR.

Authors:  Huijuan Wang; Hailong Zhang; Pengchi Deng; Chunqi Liu; Dandan Li; Hui Jie; Hu Zhang; Zongguang Zhou; Ying-Lan Zhao
Journal:  BMC Cancer       Date:  2016-06-29       Impact factor: 4.430

9.  Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: A pilot control-case study in Colombian Hispanic women.

Authors:  Mónica P Cala; Julian Aldana; Jessica Medina; Julián Sánchez; José Guio; Julien Wist; Roland J W Meesters
Journal:  PLoS One       Date:  2018-02-13       Impact factor: 3.240

10.  Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.

Authors:  Linda S Steelman; Steve L Abrams; Peter Ruvolo; Vivian Ruvolo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Luca M Neri; Saverio Candido; Massimo Libra; James A McCubrey
Journal:  Oncotarget       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.